ArticleThe Journal of clinical investigation2006
Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 140 citations in OpenAlex.
- CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX-5+ Tumour-Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours.Veterinary and comparative oncology · 2026Article
- A preclinical study of device dependent therapeutic effects of cold atmospheric plasmas on atopic dermatitis induced by DNCB.Scientific reports · 2026Article
- Chemokine ligand-receptor interactions as potential therapeutic targets for atopic dermatitis: from basic to clinical research.Frontiers in allergy · 2026Review
- Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention.Clinical reviews in allergy & immunology · 2025Review
- Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.Communications biology · 2024Article
- Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?Journal of psoriasis and psoriatic arthritis · 2023Article
- Article
- T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis.Frontiers in immunology · 2023Review
- Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.Frontiers in oncology · 2023Review
- Mast Cell Modulation of B Cell Responses: An Under-Appreciated Partnership in Host Defence.Frontiers in immunology · 2021Review
- Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses.The Journal of allergy and clinical immunology · 2020Article
- Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma.Frontiers in immunology · 2020Review
- Mast cell peptidases (carboxypeptidase A and chymase)-mediated hydrolysis of human angiotensin-(1-12) substrate.Biochemical and biophysical research communications · 2019Article
- Mast Cells and Sensory Nerves Contribute to Neurogenic Inflammation and Pruritus in Chronic Skin Inflammation.Frontiers in cellular neuroscience · 2019Review
- Primary cutaneous anaplastic large cell lymphoma arising from a long-standing erythema nodosum: A case report.Medicine · 2018Article
- Mast cell-neural interactions contribute to pain and itch.Immunological reviews · 2018Review
- Interferon α2 and interferon γ induce the degranulation independent production of VEGF-A and IL-1 receptor antagonist and other mediators from human mast cells.Immunity, inflammation and disease · 2018Article
- CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling.BioMed research international · 2018Article
- The impact of senescence-associated T cells on immunosenescence and age-related disorders.Inflammation and regeneration · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells are involved in many disorders where the triggering mechanism that leads to degranulation and/or cytokine secretion has not been defined. Several chronic inflammatory diseases are associated with increased mast cell numbers and upregulation of the TNF receptor family member CD30, but the role of elevated CD30 expression is poorly understood. Here we report what we believe to be a novel way to activate mast cells with CD30 that leads to degranulation-independent secretion of chemokines. CD30 induced a de novo synthesis and secretion of the chemokines IL-8, macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta, a process involving the MAPK/ERK pathway. Mast cells were found to be the predominant CD30 ligand-positive (CD30L-positive) cell in the chronic inflammatory skin diseases psoriasis and atopic dermatitis, and both CD30 and CD30L expression were upregulated in lesional skin in these conditions. Furthermore, the number of IL-8-positive mast cells was elevated both in psoriatic and atopic dermatitis lesional skin as well as in ex vivo CD30-treated healthy skin organ cultures. In summary, characterization of CD30 activation of mast cells has uncovered an IgE-independent pathway that is of importance in understanding the entirety of the role of mast cells in diseases associated with mast cells and CD30 expression. These diseases include Hodgkin lymphoma, atopic dermatitis, and psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.